Single-Cell Immune Mapping of Melanoma Sentinel Lymph Nodes Reveals an Actionable Immunotolerant Microenvironment.
Kavitha YaddanapudiBryce F StampPriyanka B SubrahmanyamAndrei SmolenkovSabine J WaigelRahul GosainMichael E EggerRobert C G MartinRobert BuscagliaHolden T MaeckerKelly M McMastersJason A ChesneyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Our data suggest that these immunologic changes compromise antimelanoma immunity and contribute to a high relapse rate. We propose the development of clinical trials to test the neo-adjuvant administration of anti-PD-1 antibodies prior to SLN resection in patients with stage III melanoma. See related commentary by Lund, p. 1996.
Keyphrases
- lymph node
- clinical trial
- single cell
- sentinel lymph node
- skin cancer
- early stage
- rna seq
- stem cells
- high resolution
- high throughput
- big data
- basal cell carcinoma
- squamous cell carcinoma
- free survival
- neoadjuvant chemotherapy
- machine learning
- mass spectrometry
- high density
- open label
- phase ii
- phase iii
- artificial intelligence